• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物信息学分析和实验验证 DHODH 在透明细胞肾细胞癌中的促癌作用。

Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma.

机构信息

Department of Urology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361000, China.

School of Medicine, Xiamen University, Xiamen, 361000, China.

出版信息

Sci Rep. 2024 May 25;14(1):11985. doi: 10.1038/s41598-024-62738-0.

DOI:10.1038/s41598-024-62738-0
PMID:38796629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11127953/
Abstract

Clear cell renal cell carcinoma (ccRCC) is a malignant tumor of the urinary system. To explore the potential mechanisms of DHODH in ccRCC, we analyzed its molecular characteristics using public databases. TCGA pan-cancer dataset was used to analyze DHODH expression in different cancer types and TCGA ccRCC dataset was used to assess differential expression, prognosis correlation, immune infiltration, single-gene, and functional enrichment due to DHODH. The GSCALite and CellMiner databases were employed to explore drugs and perform molecular docking analysis with DHODH. Protein-protein interaction networks and ceRNA regulatory networks of DHODH were constructed using multiple databases. The effect of DHODH on ccRCC was confirmed in vitro. DHODH was highly expressed in ccRCC. Immune infiltration analysis revealed that DHODH may be involved in regulating the infiltration of immunosuppressive cells such as Tregs. Notably, DHODH influenced ccRCC progression by forming regulatory networks with molecules, such as hsa-miR-26b-5p and UMPS and significantly enhanced the malignant characteristics of ccRCC cells. Several drugs, such as lapatinib, silmitasertib, itraconazole, and dasatinib, were sensitive to DHODH expression and exhibited strong molecular binding with it. Thus, DHODH may promote ccRCC progression and is a candidate effective therapeutic target for ccRCC.

摘要

透明细胞肾细胞癌 (ccRCC) 是一种泌尿系统的恶性肿瘤。为了探讨 DHODH 在 ccRCC 中的潜在机制,我们使用公共数据库分析了其分子特征。TCGA 泛癌数据集用于分析不同癌症类型中 DHODH 的表达,TCGA ccRCC 数据集用于评估由于 DHODH 导致的差异表达、预后相关性、免疫浸润、单基因和功能富集。使用 GSCALite 和 CellMiner 数据库探索药物并与 DHODH 进行分子对接分析。使用多个数据库构建 DHODH 的蛋白质-蛋白质相互作用网络和 ceRNA 调控网络。在体外验证了 DHODH 对 ccRCC 的影响。DHODH 在 ccRCC 中高表达。免疫浸润分析表明,DHODH 可能参与调节 Tregs 等免疫抑制细胞的浸润。值得注意的是,DHODH 通过与 hsa-miR-26b-5p 和 UMPS 等分子形成调控网络,显著增强 ccRCC 细胞的恶性特征,从而影响 ccRCC 的进展。几种药物,如拉帕替尼、西米替丁、伊曲康唑和达沙替尼,对 DHODH 的表达敏感,并与 DHODH 具有很强的分子结合。因此,DHODH 可能促进 ccRCC 的进展,是 ccRCC 的一个候选有效治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/17248c0d652b/41598_2024_62738_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/3bc3d25bb4f2/41598_2024_62738_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/cc7a6ba0b3bb/41598_2024_62738_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/cd7212ef2190/41598_2024_62738_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/d610629f86b1/41598_2024_62738_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/b86563711e0e/41598_2024_62738_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/b7752dd8bd79/41598_2024_62738_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/2fe912dab1db/41598_2024_62738_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/e00ca52abe4d/41598_2024_62738_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/17248c0d652b/41598_2024_62738_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/3bc3d25bb4f2/41598_2024_62738_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/cc7a6ba0b3bb/41598_2024_62738_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/cd7212ef2190/41598_2024_62738_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/d610629f86b1/41598_2024_62738_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/b86563711e0e/41598_2024_62738_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/b7752dd8bd79/41598_2024_62738_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/2fe912dab1db/41598_2024_62738_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/e00ca52abe4d/41598_2024_62738_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5e3/11127953/17248c0d652b/41598_2024_62738_Fig9_HTML.jpg

相似文献

1
Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma.生物信息学分析和实验验证 DHODH 在透明细胞肾细胞癌中的促癌作用。
Sci Rep. 2024 May 25;14(1):11985. doi: 10.1038/s41598-024-62738-0.
2
Bioinformatics analysis to disclose shared molecular mechanisms between type-2 diabetes and clear-cell renal-cell carcinoma, and therapeutic indications.生物信息学分析揭示 2 型糖尿病与透明细胞肾细胞癌之间的共享分子机制及治疗指征。
Sci Rep. 2024 Aug 19;14(1):19133. doi: 10.1038/s41598-024-69302-w.
3
Construction of circRNA-based ceRNA network to reveal the role of circRNAs in the progression and prognosis of metastatic clear cell renal cell carcinoma.构建基于 circRNA 的 ceRNA 网络,揭示 circRNAs 在转移性透明细胞肾细胞癌进展和预后中的作用。
Aging (Albany NY). 2020 Nov 20;12(23):24184-24207. doi: 10.18632/aging.104107.
4
Comprehensive analysis of ceRNA networks to determine genes related to prognosis, overall survival, and immune infiltration in clear cell renal carcinoma.综合分析 ceRNA 网络,确定与透明细胞肾细胞癌预后、总生存期和免疫浸润相关的基因。
Comput Biol Med. 2022 Feb;141:105043. doi: 10.1016/j.compbiomed.2021.105043. Epub 2021 Nov 20.
5
Circular RNA hsa_circ_001895 serves as a sponge of microRNA-296-5p to promote clear cell renal cell carcinoma progression by regulating SOX12.环状 RNA hsa_circ_001895 作为 microRNA-296-5p 的海绵,通过调节 SOX12 促进肾透明细胞癌的进展。
Cancer Sci. 2020 Feb;111(2):713-726. doi: 10.1111/cas.14261. Epub 2019 Dec 30.
6
Delivery of miR-224-5p by Exosomes from Cancer-Associated Fibroblasts Potentiates Progression of Clear Cell Renal Cell Carcinoma.肿瘤相关成纤维细胞来源的外泌体递送 miR-224-5p 促进肾透明细胞癌进展。
Comput Math Methods Med. 2021 May 24;2021:5517747. doi: 10.1155/2021/5517747. eCollection 2021.
7
Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma.构建 circRNA/miRNA/mRNA 调控网络,探索透明细胞肾细胞癌的潜在发病机制和治疗选择。
Sci Rep. 2020 Aug 12;10(1):13659. doi: 10.1038/s41598-020-70484-2.
8
MiR-212-5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15.miR-212-5p 通过靶向 TBX15 抑制肾透明细胞癌细胞的恶性行为。
Eur Rev Med Pharmacol Sci. 2019 Dec;23(24):10699-10707. doi: 10.26355/eurrev_201912_19770.
9
miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression.miR-19a通过促进细胞增殖和抑制PTEN/SMAD4表达与透明细胞肾细胞癌患者的不良预后相关。
Int J Oncol. 2016 Dec;49(6):2589-2599. doi: 10.3892/ijo.2016.3746. Epub 2016 Oct 24.
10
miR-155-5p Promotes Cell Proliferation and Migration of Clear Cell Renal Cell Carcinoma by Targeting PEG3.miR-155-5p 通过靶向 PEG3 促进透明细胞肾细胞癌的细胞增殖和迁移。
Urol Int. 2021;105(9-10):906-915. doi: 10.1159/000514416. Epub 2021 Jun 30.

引用本文的文献

1
Uridine as a hub in cancer metabolism and RNA biology.尿苷作为癌症代谢和RNA生物学的核心。
Exp Mol Med. 2025 Aug 14. doi: 10.1038/s12276-025-01402-7.
2
KRAS mutation promotes the colonization of Fusobacterium nucleatum in colorectal cancer by down-regulating SERTAD4.KRAS 突变通过下调 SERTAD4 促进具核梭杆菌在结直肠癌中的定植。
J Cell Mol Med. 2024 Oct;28(20):e70182. doi: 10.1111/jcmm.70182.
3
Lapatinib: A Potential Therapeutic Agent for Colon Cancer Targeting Ferroptosis.拉帕替尼:一种靶向铁死亡的结肠癌潜在治疗药物。

本文引用的文献

1
RUVBL1 in Clear-Cell Renal Cell Carcinoma: Unraveling Prognostic Significance and Correlation with HIF1A.透明细胞肾细胞癌中的RUVBL1:揭示预后意义及与HIF1A的相关性
Cancers (Basel). 2024 Mar 25;16(7):1273. doi: 10.3390/cancers16071273.
2
PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma.PABPC1L 通过诱导 IDO1 促进肾细胞癌中的色氨酸代谢和免疫抑制。
Cancer Res. 2024 May 15;84(10):1659-1679. doi: 10.1158/0008-5472.CAN-23-2521.
3
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Anticancer Agents Med Chem. 2025;25(2):114-123. doi: 10.2174/0118715206327756240830062531.
新兴免疫疗法在晚期透明细胞肾细胞癌中的应用。
Cells. 2023 Dec 22;13(1):34. doi: 10.3390/cells13010034.
4
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.ECOG 体能状况对癌症患者免疫治疗和免疫联合治疗疗效的影响:MOUSEION-06 研究。
Clin Exp Med. 2023 Dec;23(8):5039-5049. doi: 10.1007/s10238-023-01159-1. Epub 2023 Aug 3.
5
De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence.从头合成嘧啶生物合成复合物支持癌细胞增殖和铁死亡防御。
Nat Cell Biol. 2023 Jun;25(6):836-847. doi: 10.1038/s41556-023-01146-4. Epub 2023 Jun 8.
6
Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase.赖氨酰氧化酶样蛋白 3 通过稳定二氢乳清酸脱氢酶抑制线粒体铁死亡从而促进肝癌化疗耐药性。
Nat Commun. 2023 May 30;14(1):3123. doi: 10.1038/s41467-023-38753-6.
7
Comprehensive bioinformatics and experimental analysis of SH3PXD2B reveals its carcinogenic effect in gastric carcinoma.全面的生物信息学和实验分析表明 SH3PXD2B 可促进胃癌的发生。
Life Sci. 2023 Aug 1;326:121792. doi: 10.1016/j.lfs.2023.121792. Epub 2023 May 19.
8
Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases.Cdc2 样激酶:结构、生物学功能及疾病治疗靶点。
Signal Transduct Target Ther. 2023 Apr 7;8(1):148. doi: 10.1038/s41392-023-01409-4.
9
LZTFL1 inhibits kidney tumor cell growth by destabilizing AKT through ZNRF1-mediated ubiquitin proteosome pathway.LZTFL1 通过 ZNRF1 介导的泛素蛋白酶体途径破坏 AKT 从而抑制肾肿瘤细胞生长。
Oncogene. 2023 May;42(19):1543-1557. doi: 10.1038/s41388-023-02666-x. Epub 2023 Mar 25.
10
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.EHBP1L1 通过结合和稳定 JAK1 驱动肾细胞癌中的免疫逃逸。
Adv Sci (Weinh). 2023 Apr;10(11):e2206792. doi: 10.1002/advs.202206792. Epub 2023 Feb 12.